Literature DB >> 20413503

Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults.

Calman A MacLennan1, James J Gilchrist, Melita A Gordon, Adam F Cunningham, Mark Cobbold, Margaret Goodall, Robert A Kingsley, Joep J G van Oosterhout, Chisomo L Msefula, Wilson L Mandala, Denisse L Leyton, Jennifer L Marshall, Esther N Gondwe, Saeeda Bobat, Constantino López-Macías, Rainer Doffinger, Ian R Henderson, Eduard E Zijlstra, Gordon Dougan, Mark T Drayson, Ian C M MacLennan, Malcolm E Molyneux.   

Abstract

Nontyphoidal Salmonellae are a major cause of life-threatening bacteremia among HIV-infected individuals. Although cell-mediated immunity controls intracellular infection, antibodies protect against Salmonella bacteremia. We report that high-titer antibodies specific for Salmonella lipopolysaccharide (LPS) are associated with a lack of Salmonella-killing in HIV-infected African adults. Killing was restored by genetically shortening LPS from the target Salmonella or removing LPS-specific antibodies from serum. Complement-mediated killing of Salmonella by healthy serum is shown to be induced specifically by antibodies against outer membrane proteins. This killing is lost when excess antibody against Salmonella LPS is added. Thus, our study indicates that impaired immunity against nontyphoidal Salmonella bacteremia in HIV infection results from excess inhibitory antibodies against Salmonella LPS, whereas serum killing of Salmonella is induced by antibodies against outer membrane proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413503      PMCID: PMC3772309          DOI: 10.1126/science.1180346

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  31 in total

1.  Epidemiology of nontyphoidal Salmonella bacteremia during the human immunodeficiency virus epidemic.

Authors:  W C Levine; J W Buehler; N H Bean; R V Tauxe
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

2.  Acquired immune deficiency syndrome in Black Africans.

Authors:  N Clumeck; F Mascart-Lemone; J de Maubeuge; D Brenez; L Marcelis
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

3.  Bacteremia among children admitted to a rural hospital in Kenya.

Authors:  James A Berkley; Brett S Lowe; Isaiah Mwangi; Thomas Williams; Evasius Bauni; Saleem Mwarumba; Caroline Ngetsa; Mary P E Slack; Sally Njenga; C Anthony Hart; Kathryn Maitland; Mike English; Kevin Marsh; J Anthony G Scott
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

4.  Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans.

Authors:  Calman MacLennan; Claire Fieschi; David A Lammas; Capucine Picard; Susan E Dorman; Ozden Sanal; Jenny M MacLennan; Steven M Holland; Tom H M Ottenhoff; Jean-Laurent Casanova; Dinakantha S Kumararatne
Journal:  J Infect Dis       Date:  2004-10-07       Impact factor: 5.226

Review 5.  Diverse virulence traits underlying different clinical outcomes of Salmonella infection.

Authors:  J Fierer; D G Guiney
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

6.  Pathogens and predictors of fatal septicemia associated with human immunodeficiency virus infection in Ivory Coast, west Africa.

Authors:  D J Vugia; J A Kiehlbauch; K Yeboue; J M N'Gbichi; D Lacina; M Maran; M Gondo; K Kouadio; A Kadio; S B Lucas
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

7.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

8.  Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.

Authors:  A Shirai; M Cosentino; S F Leitman-Klinman; D M Klinman
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

9.  Salmonella infections in patients with the acquired immunodeficiency syndrome.

Authors:  J L Jacobs; J W Gold; H W Murray; R B Roberts; D Armstrong
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

10.  HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization.

Authors:  Mathurin C Tejiokem; Ionela Gouandjika; Lydie Béniguel; Marie-Claire Endegue Zanga; Gilbert Tene; Jean C Gody; Elisabeth Njamkepo; Anfumbom Kfutwah; Ida Penda; Catherine Bilong; Dominique Rousset; Régis Pouillot; Frédéric Tangy; Laurence Baril
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

View more
  78 in total

1.  Subversion of innate and adaptive immune activation induced by structurally modified lipopolysaccharide from Salmonella typhimurium.

Authors:  Rodolfo Pastelin-Palacios; Cristina Gil-Cruz; Christian I Pérez-Shibayama; Mario A Moreno-Eutimio; Luisa Cervantes-Barragán; Lourdes Arriaga-Pizano; Burkhard Ludewig; Adam F Cunningham; Eduardo A García-Zepeda; Ingeborg Becker; Celia Alpuche-Aranda; Laura Bonifaz; John S Gunn; Armando Isibasi; Constantino López-Macías
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

2.  Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection.

Authors:  Jonathan R Kurtz; Hailey E Petersen; Daniel R Frederick; Lisa A Morici; James B McLachlan
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Comparing the roles of antibodies to nontyphoidal Salmonella enterica in high- and low-income countries and implications for vaccine development.

Authors:  Calman A MacLennan; Sharon M Tennant
Journal:  Clin Vaccine Immunol       Date:  2013-07-31

4.  Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties.

Authors:  Mario A Moreno-Eutimio; Alejandra Tenorio-Calvo; Rodolfo Pastelin-Palacios; Christian Perez-Shibayama; Cristina Gil-Cruz; Rubén López-Santiago; Isabel Baeza; Marcos Fernández-Mora; Laura Bonifaz; Armando Isibasi; Edmundo Calva; Constantino López-Macías
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 5.  Antibodies and Protection in Systemic Salmonella Infections: Do We Still Have More Questions than Answers?

Authors:  Pietro Mastroeni; Omar Rossi
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

Review 6.  Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.

Authors:  Raphael Simon; Myron M Levine
Journal:  Hum Vaccin Immunother       Date:  2012-02-28       Impact factor: 3.452

7.  Role of antilipopolysaccharide antibodies in serum bactericidal activity against Salmonella enterica serovar Typhimurium in healthy adults and children in the United States.

Authors:  Estela Trebicka; Susan Jacob; Waheed Pirzai; Bryan P Hurley; Bobby J Cherayil
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

Review 8.  Antimicrobial resistance and management of invasive Salmonella disease.

Authors:  Samuel Kariuki; Melita A Gordon; Nicholas Feasey; Christopher M Parry
Journal:  Vaccine       Date:  2015-04-23       Impact factor: 3.641

9.  Early interferon-γ production in human lymphocyte subsets in response to nontyphoidal Salmonella demonstrates inherent capacity in innate cells.

Authors:  Tonney S Nyirenda; Anna E Seeley; Wilson L Mandala; Mark T Drayson; Calman A MacLennan
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  Cutting edge: B cells are essential for protective immunity against Salmonella independent of antibody secretion.

Authors:  Minelva R Nanton; Sing Sing Way; Mark J Shlomchik; Stephen J McSorley
Journal:  J Immunol       Date:  2012-11-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.